Prosecution Insights
Last updated: November 12, 2026
Application No. 18/755,462

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING MUCOSAL TISSUE DAMAGE OR DISEASE

Non-Final OA §102§103
Filed
Jun 26, 2024
Priority
Jan 06, 2022 — provisional 63/266,464 +1 more
Examiner
HOFFMAN, SUSAN COE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mebo International Inc.
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
79%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
591 granted / 1094 resolved
-6.0% vs TC avg
Strong +25% interview lift
Without
With
+25.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
65 currently pending
Career history
1175
Total Applications
across all art units

Office Action

§102 §103
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. Claims 1-21 are currently pending. Election/Restrictions 3. Applicant’s election without traverse of beta-sitosterol for species A, beeswax for species B, sesame oil for species C, and huangqin for species D in the reply filed on August 19, 2026 is acknowledged. 4. Claims 15, 17, and 18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. 5. Claims 1-14, 16, and 19-21 are examined on the merits in regards to the elected species. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 6. Claim(s) 1-14, 16, 19, and 20 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Xu (US 7,211,276). Xu teaches a method for repairing damaged mucosal tissue in a patient by orally administering a composition an edible oil homogenized with an edible wax at a concentration ranging from 0.5% to 50% by weight and a sterol compound at a concentration of at least 0.1%, where the edible oil, the edible wax and the sterol compound are homogenized to form a colloid with the edible wax adopting a microcrystal form at ambient temperature where the size of the microcrystals are 0.1-100 micrometers in length. The reference teaches that the microcrystals are dispersed uniformly in the oil. The reference teaches that the sterol can be beta-sitosterol, that the wax can be beeswax, and the oil can be sesame oil. The reference teaches that the sterol can be present at 0.5 to 20% or 1 to 10% by weight. The reference teaches that the wax is present at 3 to 30% by weight (see column 3, lines 6-45 and column 4, lines 4-17 and 46 and the claims). The reference teaches that the composition contains less than 1% water by weight (see column 3, lines 51-54 and claim 19). The reference teaches that the composition is administered at 0.5 to 10 g per day or 2-8 g per day. In addition, the reference teaches that the composition can be formulated into a hard gel capsule or 0.5 g soft gel capsule where 1-10 of the capsules are administered twice a day (see column 6, lines 58-63 and claims 3-6 and 22). The reference teaches that the composition can also contain an extract of huangqin (see claim 24). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 7. Claim(s) 1 and 21 is/are rejected under 35 U.S.C. 103 as being unpatentable over Xu (US 7,211,276) in view of Senior ("Can Sesame Oil Extract Help Treat Crohn's Disease? Researchers Seeking Participants in Trial", College of Medicine: University of Central Florida Internet News, August 29, 2018, 2 pgs). The teachings of Xu are discussed above. The reference teaches that the composition can repair mucosal tissue damage caused by a gastrointestinal disorder in general (see claim 33). However, the reference does not specifically teach treating damage caused by Crohn’s disease in particular. However, Crohn’s disease is a gastrointestinal disorder known to cause mucosal damage. In addition, Senior teaches that sesame oil can be useful in treating Crohn’s disease. Thus, an artisan of would reasonably expect that the sesame oil containing tissue repairing composition taught by Xu would be useful for treating damage caused by Crohn’s disease in particular because sesame oil was known to be useful in treating this disease. This reasonable expectation of success would have motivated the artisan to modify Xu to specifically teach damage caused by Crohn’s disease. 8. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Hoffman whose telephone number is (571)272-0963. The examiner can normally be reached M-Th 8:30am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSAN HOFFMAN/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Jun 26, 2024
Application Filed
Oct 23, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788793
BONCHONGMYUNGTANG COMPOSITION FOR IMPROVING MEMORY AND LEARNING ABILITY
1y 7m to grant Granted Nov 10, 2026
Patent 12779000
Processes for Extracting Muscimol from Amanita Muscaria
3y 1m to grant Granted Nov 03, 2026
Patent 12766178
SKIN CLARIFIER
5y 0m to grant Granted Oct 20, 2026
Patent 12766176
DEBITTERING KUDINGCHA EXTRACT, PREPARATION METHOD AND FINGERPRINT DETECTION METHOD THEREOF
3y 8m to grant Granted Oct 20, 2026
Patent 12766180
Fagopyrum Nutraceutical Compositions
2y 7m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
79%
With Interview (+25.4%)
Low
PTA Risk
Based on 1094 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month